Xencor, Inc. (XNCR)
| Market Cap | 891.06M |
| Revenue (ttm) | 125.58M |
| Net Income (ttm) | -91.92M |
| Shares Out | 73.34M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,045,190 |
| Open | 13.05 |
| Previous Close | 13.10 |
| Day's Range | 11.89 - 13.35 |
| 52-Week Range | 6.92 - 18.69 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 22.33 (+83.79%) |
| Earnings Date | May 8, 2026 |
About XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase... [Read more]
Financial Performance
In 2025, Xencor's revenue was $125.58 million, an increase of 13.65% compared to the previous year's $110.49 million. Losses were -$91.92 million, -60.48% less than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for XNCR stock is "Buy." The 12-month stock price target is $22.33, which is an increase of 83.79% from the latest price.
News
Xencor Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted progress in oncology and immunology pipelines, with pivotal trial plans for lead T-cell engagers in 2027 and robust data supporting expansion into earlier therapy lines. Long-acting TL1A and bispecific programs in IBD aim for best-in-class efficacy and broad market reach.
Xencor Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a robust pipeline of bispecific antibodies in oncology and autoimmune diseases, with key programs XmAb819 and XmAb541 progressing toward pivotal trials and market expansion into new tumor types. Autoimmune efforts focus on TL1A-targeting molecules, with significant data updates expected in 2024.
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Transcript: TD Cowen 46th Annual Health Care Conference
The organization is advancing a robust pipeline in oncology and autoimmune diseases, highlighted by pivotal studies for XmAb819 and XmAb942, and innovative programs like XmAb412 and XmAb657. Strong financials and strategic partnerships support clinical execution and future growth.
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor to Participate at Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Transcript: Piper Sandler 37th Annual Healthcare Conference
The conference highlighted robust progress in autoimmune and oncology pipelines, including promising phase I/II data for XmAb942 and XmAb819, and strategic partnerships with Amgen and J&J. Multiple pivotal data readouts are expected by 2026, with strong funding through 2028.
Xencor Transcript: TD Cowen Immunology and Inflammation Summit
The summit highlighted a focused strategy on T-cell engagers in oncology and innovative autoimmune therapies, including advanced TL1A and bispecific antibodies. Key programs are progressing through global clinical trials, with differentiation based on potency, dosing convenience, and targeted patient populations.
Xencor Reports Third Quarter 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor Transcript: Study Result
Initial phase I results for XmAb819 in advanced RCC show a 25% response rate and 70% disease control in heavily pretreated patients, with a favorable safety profile and manageable CRS. Enrollment is strong, and further expansion and combination studies are planned.
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will hos...
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Transcript: Cantor Global Healthcare Conference 2025
The conference highlighted strategic advances in immunology and oncology, with key updates on XmAb819 for renal cell carcinoma and the TL1A program for IBD. Upcoming clinical data, innovative bispecific designs, and a focus on durable therapies underscore a robust pipeline.
Xencor Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
A strategic reset has focused the pipeline on high-probability oncology and autoimmune programs, leveraging a validated protein engineering platform. Key milestones include Phase 2b data for XmAb942, first-in-human studies for ZNP53, and oncology readouts for XmAb819 and XmAb541.
Xencor Reports Second Quarter 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Reports First Quarter 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor Transcript: Investor Update
XmAb942 demonstrated strong safety, long half-life, and durable TL1A suppression in phase I, supporting Q12-week dosing for ulcerative colitis. The pipeline includes a TL1A-IL-23 bispecific, with combination therapy seen as key to future IBD treatment. Patient convenience and high drug exposure are central to the development strategy.
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Appoints Todd Simpson to Board of Directors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
